Elisabetta Pupillo

Dr. Elisabetta Pupillo

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2016 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PRParals Registry
Parals Registry
WRWouter van Rheenen
Wouter van Rheenen
SGSLALOM Group
SLALOM Group
SRSlap Registry
Slap Registry
FCFALS Sequencing Consortium
FALS Sequencing Consortium
JVJan H Veldink
Jan H Veldink

2 January 2014 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
EPElisabetta Pupillo
Elisabetta Pupillo
PMPaolo Messina
Paolo Messina
GLGiancarlo Logroscino
Giancarlo Logroscino
EBEttore Beghi
Ettore Beghi
Massimiliano FilostoMassimiliano Filosto
Massimiliano Filosto

11 August 2010 in Amyotrophic Lateral Sclerosis
Verified
Journal Article
Closed access
PDF file
EBEttore Beghi
Ettore Beghi
ACAdriano Chiò
Adriano Chiò
PCPhilippe Couratier
Philippe Couratier
JEJesùs Esteban
Jesùs Esteban
OHOrla Hardiman
Orla Hardiman
O(On Behalf Of The Eurals Consortium (*)
On Behalf Of The Eurals Consortium (*)
Effective treatments for amyotrophic lateral sclerosis (ALS) have remained elusive. Only riluzole, a drug thought to affect glutamate metabolism, improves survival albeit to modest extent. Explanations for the negative results of therapeutic trials include a likely heterogeneity, both in disease susceptibility and pathogenic mechanisms, and faulty methodology of clinical trials. Further understanding of these factors will lead to improvements in patient stratification, and in the design of future clinical trials.

5 April 2014 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
EPElisabetta Pupillo
Elisabetta Pupillo
PMPaolo Messina
Paolo Messina
GGGiorgia Giussani
Giorgia Giussani
GLGiancarlo Logroscino
Giancarlo Logroscino
SZStefano Zoccolella
Stefano Zoccolella
TCthe EURALS Consortium
the EURALS Consortium

1 January 2015 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
CCCarlo Cianchetti
Carlo Cianchetti
PMPaolo Messina
Paolo Messina
EPElisabetta Pupillo
Elisabetta Pupillo
GCGiovanni Crichiutti
Giovanni Crichiutti
MBMaria Giuseppina Baglietto
Maria Giuseppina Baglietto
EBEttore Beghi
Ettore Beghi

4 January 2013 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Verified
Journal Article
Closed access
PDF file
EBEttore Beghi
Ettore Beghi
EPElisabetta Pupillo
Elisabetta Pupillo
VBVirginio Bonito
Virginio Bonito
PBPaolo Buzzi
Paolo Buzzi
CCClaudia Caponnetto
Claudia Caponnetto
TGThe Italian ALS Study Group
The Italian ALS Study Group
Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS). Definite/probable ALS patients, 40−70 years of age, duration 6−24 months, self-sufficient (i.e. able to swallow, cut food/handle utensils, and walk), and with forced vital capacity (FVC) > 80% entered a pilot double-blind, placebo-controlled, parallel group trial and were followed for 48 weeks. ALC or placebo 3 g/day was added to riluzole 100 mg/day. Primary endpoint: number of patients no longer self-sufficient. Secondary endpoints: changes in ALSFRS-R, MRC, FVC and McGill Quality of Life (QoL) scores. Analysis was made in the intention-to-treat (ITT) and per-protocol (PP) population, completers and completers/compliers (i.e. taking > 75% of study drug). Forty-two patients received ALC and 40 placebo. In the ITT population, 34 (80.9%) patients receiving ALC and 39 (97.5%) receiving placebo became non-self-sufficient (p = 0.0296). In the PP analysis, percentages were 84.4 and 100.0% (p = 0.0538), respectively. Mean ALSFRS-R scores at 48 weeks were 33.6 (SD 10.4) and 27.6 (9.9) (p = 0.0388), respectively, and mean FVC scores 90.3 (32.6) and 58.6 (31.2) (p = 0.0158), respectively. Median survival was 45 months (ALC) and 22 months (placebo) (p = 0.0176). MRC, QoL and adverse events were similar. In conclusion, ALC may be effective, well-tolerated and safe in ALS. A pivotal phase III trial is needed.